USFDA issues 7 observations to NATCO Pharma's Hyderabad facility

Wait 5 sec.

NATCO Pharma Limited reported receiving seven observations from the USFDA following an inspection of its manufacturing facility. The inspection took place from November 12 to November 20 in Hyderabad. The company stated that the issued Form 483 highlights procedural observations as potential violations. NATCO Pharma expressed confidence in addressing the observations within specified timelines. The company aims to resolve these issues comprehensively and ensure compliance going forward.